New treatments for relapsed refractory multiple myeloma highlighted at ASH

NEW ORLEANS — In this video perspective, Rahul Banerjee, MD, FACPdiscusses research on new treatments for relapsed refractory multiple myeloma presented at the ASH Annual Meeting and Exposition.

A study highlighted by Banerjee, an assistant professor at the University of Washington, explored the dosage of mezigdomide and dexamethasone in patients with triple-class refractory multiple myeloma. The overall response rate was 40.6 percent in all patients, but most importantly, in those who had received prior B-cell maturation antigen therapy, the overall response rate was 50 percent, he said. Banerjee.

“As ide-cel and CAR-T therapy move to older lines of therapy, as bispecifics move to older lines of therapy – the vast majority of which target BCMA – we will have more and more patients who are BCMA-refractory or under-exposed to BCMA ‘ Banerjee said. “Some data will be quadruple class refractory for patients who also received BCMA therapies and for those patients, the fact that an all-oral doublet regimen achieves a 50% overall response rate is phenomenal.”

Banerjee also highlighted data from a multicenter Phase 1 study investigating CC98633/BMS-986354 in patients with relapsed refractory myeloma, which showed an ORR of 95% at all dose levels.

References:

• Megala Costa LJ, et al. Abstract 566. Presented at: ASH Annual Meeting and Exposition; 10-13 December 2022; New Orleans.
• Richardson PG, et al. Abstract 568. Presented at: ASH Annual Meeting and Exposition; 10-13 December 2022; New Orleans.

ADD A TOPIC TO E-MAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

” data-action=subscribe> Subscribe

We were unable to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

Let’s go back to Healio

Take houses in multiple myeloma